Rehabilitation benefits for advanced NSCLC patients with stable disease after 6+ months of treatment
Official title: Study of Three Endpoints to Assess the Benefit of Rehabilitation in Patients With Advanced Non-small Cell Lung Cancer Controlled After at Least 6 Months of Systemic Treatment
Run by University Hospital, Grenoble · NCT07434947 · Data updated 2026-11-12
This study tests a 3-month rehabilitation program to see how it helps people with advanced NSCLC who have had stable disease for at least 6 months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 63 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 3 sites (Annecy and 2 other locations) |
| Status | Recruiting |
| Started | April 15, 2026 |
| Main results expected | October 14, 2027 |
| Study ends | October 14, 2027 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07434947 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with locally advanced or metastatic NSCLC, ECOG 0-2, whose disease has been controlled for at least six months and who report functional limitations.
✕Probably not a fit
Patients without functional limitations or those with very limited life expectancy may be less likely to show measurable rehabilitation benefits.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter observational study aims to identify the most relevant outcome measure for evaluating rehabilitation benefits in adults with locally advanced or metastatic NSCLC whose disease has remained controlled for at least six months. Participants will engage in a rehabilitation program delivered in hospital, rehabilitation units, or at home, depending on local practice, with the goal of improving physical function and qualy. The study will collect data on patients’ fatigue, activity levels, and quality of life to determine which outcome best reflects benefit.
Why it matters
Potential benefit: If successful, the study could clarify which patient-reported or objective outcomes best capture the benefits of rehabilitation for this group.
How similar studies have gone: There is prior evidence of benefits from rehabilitation in earlier-stage NSCLC and perioperative settings, but data in this specific, advanced-and-controlled population are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients treated for NSCLC at CHUGA, CHMS, or CHANGE * Locally advanced or metastatic NSCLC * Tumor disease controlled for at least 6 months following any type of anti-tumor treatment * ECOG Performance Status 0 to 2 * Patient reporting functional complaints related to physical activity * Covered by the national health insurance system Exclusion Criteria: * Initial management of the tumor disease started ≥ 2 years ago * Residual toxicity of grade ≥ 2 * Estimated life expectancy less than 6 months (at the discretion of the investigator) * Patient with an absolute contraindication to physical activity at the time of consultation (e.g., unstable angina; acute intercurrent event...) * Subject currently in an exclusion period from another study or participating in an interventional study
Where it's running
-
CH Métropole Savoie
Chambéry, France Recruiting -
Centre Hospitalier Annecy Genevois
Annecy, France Not yet recruiting -
CHU Grenoble Alpes
Grenoble, France Not yet recruiting
Study contacts
- Principal investigator: Anne-Claire TOFFART — CHU Grenoble Alpes
- Study coordinator: Anne-Claire TOFFART
- Email: AToffart@chu-grenoble.fr
- Phone: 33 +(0)4 76 76 68 31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.